New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
MRI-guided radiotherapy produces fewer side effects, better quality of life for patients with localized prostate cancer

MRI-guided radiotherapy produces fewer side effects, better quality of life for patients with localized prostate cancer

byUniversity of California, Los AngelesCredit: CC0 Public DomainFor men who undergo radiotherapy for localized prostate cancer, the precise targeting capabilities of MRI guidance resulted in few
World medicine December 17,2023
MRI-guided radiotherapy produces fewer side effects, better quality of life for patients with localized prostate cancer

MRI-guided radiotherapy produces fewer side effects, better quality of life for patients with localized prostate cancer

byUniversity of California, Los AngelesCredit: CC0 Public DomainFor men who undergo radiotherapy for localized prostate cancer, the precise targeting capabilities of MRI guidance resulted in few
World medicine December 17,2023
Moderna's experimental cancer vaccine treats but doesn't prevent melanoma—a biochemist explains how it works

Moderna's experimental cancer vaccine treats but doesn't prevent melanoma—a biochemist explains how it works

by Mark R. O'Brian,The ConversationCredit: Pixabay/CC0 Public DomainMediaoutletshave reported the encouraging findings of clinical trials for a new experimental vaccine developed
Oncology December 17,2023
Moderna's experimental cancer vaccine treats but doesn't prevent melanoma—a biochemist explains how it works

Moderna's experimental cancer vaccine treats but doesn't prevent melanoma—a biochemist explains how it works

by Mark R. O'Brian,The ConversationCredit: Pixabay/CC0 Public DomainMediaoutletshave reported the encouraging findings of clinical trials for a new experimental vaccine developed
Oncology December 17,2023
MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor
Oncology December 17,2023
MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor
Oncology December 17,2023
MicroRNA can help predict which breast cancer patients are more likely to see their cancer come back

MicroRNA can help predict which breast cancer patients are more likely to see their cancer come back

byAmerican College of SurgeonsCredit: Pixabay/CC0 Public DomainMicroRNA (miRNA) can be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality, ac
World medicine December 17,2023
MicroRNA can help predict which breast cancer patients are more likely to see their cancer come back

MicroRNA can help predict which breast cancer patients are more likely to see their cancer come back

byAmerican College of SurgeonsCredit: Pixabay/CC0 Public DomainMicroRNA (miRNA) can be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality, ac
World medicine December 17,2023
Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer

Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer

by Impact JournalsExpression of lncRNA MVIH in CC tumor as compared to marginal non-tumor tissues. Credit:Genes & Cancer(2022). DOI: 10.18632/genesandcancer.224A new research paper was
Oncology December 17,2023
Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer

Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer

by Impact JournalsExpression of lncRNA MVIH in CC tumor as compared to marginal non-tumor tissues. Credit:Genes & Cancer(2022). DOI: 10.18632/genesandcancer.224A new research paper was
Oncology December 17,2023
KRAS mutation shown to promote tumor evasion of innate immune surveillance in lung cancer

KRAS mutation shown to promote tumor evasion of innate immune surveillance in lung cancer

by Nanjing University School of Life SciencesGraphical abstract. Credit:Journal of Clinical Investigation(2022). DOI: 10.1172/JCI153470KRAS is one of the most frequently activated oncogene
World medicine December 17,2023
KRAS mutation shown to promote tumor evasion of innate immune surveillance in lung cancer

KRAS mutation shown to promote tumor evasion of innate immune surveillance in lung cancer

by Nanjing University School of Life SciencesGraphical abstract. Credit:Journal of Clinical Investigation(2022). DOI: 10.1172/JCI153470KRAS is one of the most frequently activated oncogene
World medicine December 17,2023
Benefits persist for lenvatinib, pembrolizumab in renal cell cancer

Benefits persist for lenvatinib, pembrolizumab in renal cell cancer

by Elana GotkineFor patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study p
World medicine December 17,2023
Benefits persist for lenvatinib, pembrolizumab in renal cell cancer

Benefits persist for lenvatinib, pembrolizumab in renal cell cancer

by Elana GotkineFor patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study p
World medicine December 17,2023
Phase II trial shows addition of durvalumab to radiation does not improve outcomes over cetuximab for HNSCC patients

Phase II trial shows addition of durvalumab to radiation does not improve outcomes over cetuximab for HNSCC patients

by NRG OncologyCredit: Pixabay/CC0 Public DomainThe Phase II results of the NRG Oncology HN004 trial indicate that radiotherapy (RT) with the PD-L1 inhibitor durvalumab did not improve progression-fre
World medicine December 17,2023
Phase II trial shows addition of durvalumab to radiation does not improve outcomes over cetuximab for HNSCC patients

Phase II trial shows addition of durvalumab to radiation does not improve outcomes over cetuximab for HNSCC patients

by NRG OncologyCredit: Pixabay/CC0 Public DomainThe Phase II results of the NRG Oncology HN004 trial indicate that radiotherapy (RT) with the PD-L1 inhibitor durvalumab did not improve progression-fre
World medicine December 17,2023
New clinical guideline on radiation therapy for IDH-mutant glioma

New clinical guideline on radiation therapy for IDH-mutant glioma

byAmerican Society for Radiation OncologyWHO 2021 classification: Adult-type diffuse glioma. Abbreviations: IDH = isocitrate dehydrogenase; WHO = World Health Organization. Credit:Practica
World medicine December 17,2023
New clinical guideline on radiation therapy for IDH-mutant glioma

New clinical guideline on radiation therapy for IDH-mutant glioma

byAmerican Society for Radiation OncologyWHO 2021 classification: Adult-type diffuse glioma. Abbreviations: IDH = isocitrate dehydrogenase; WHO = World Health Organization. Credit:Practica
World medicine December 17,2023
Ide-cel beneficial in relapsed, refractory multiple myeloma

Ide-cel beneficial in relapsed, refractory multiple myeloma

by Elana GotkineFor patients with pretreated relapsed and refractory multiple myeloma, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy,
World medicine December 17,2023
Ide-cel beneficial in relapsed, refractory multiple myeloma

Ide-cel beneficial in relapsed, refractory multiple myeloma

by Elana GotkineFor patients with pretreated relapsed and refractory multiple myeloma, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy,
World medicine December 17,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com